Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound aminophenolamine is a widely used fixed-dose combination medication in China, primarily indicated for the symptomatic relief of the common cold and influenza. It typically consists of five active components: acetaminophen (paracetamol), amantadine hydrochloride, chlorpheniramine maleate, caffeine, and artificial bezoar. Acetaminophen serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Amantadine hydrochloride acts as an antiviral agent by blocking the M2 proton channel of the influenza A virus, thereby preventing viral uncoating. Chlorpheniramine maleate is a first-generation antihistamine that reduces symptoms like sneezing and rhinorrhea by antagonizing H1 receptors. Caffeine is included to counteract the sedative effects of the antihistamine and to potentially enhance the analgesic effect. Artificial bezoar, a traditional Chinese medicine component, is added for its purported antipyretic, anti-inflammatory, and sedative properties. The drug is available over-the-counter and is manufactured by numerous pharmaceutical companies across China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound aminophenolamine.